護城河比較

The FY2025 10-K (filed 2026-01-23) repeats the concession, now broadened: 'we have lost market share in recent years, including in both client and data center markets, in the market for x86-based semiconductor products, and more generally in the markets for semiconductor compute products, as competitors have introduced highly competitive data center and client platform products.' It adds that the data-center business 'has been further negatively impacted in the past few years by the significant shift of customer spend toward GPUs optimized for AI workloads' — a historically wide moat still actively eroding.

來源：sec.gov

FY2025 10-K (Item 1, filed 2026-02-09): a proprietary solid-oxide platform protected by 380 active U.S. utility patents plus 183 pending, with speed-to-power the company says can deliver onsite power 'within approximately 90 days' — real but contested advantages: the same 10-K's Item 1A calls distributed generation and hydrogen 'still emerging markets' whose acceptance is uncertain, and revenue concentration was 43%/13%/12% across three customers in FY2025 (sec.gov/Archives/edgar/data/1664703/000162828026006516/be-20251231.htm).

來源：sec.gov

The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion.

來源：sec.gov

The durable assets remain the x86 architecture and process-technology IP: the FY2025 10-K claims 'We are a global leader in the design and manufacturing of CPUs and other semiconductor products' and stakes the recovery on process IP — 'Intel 18A introduces two industry firsts in high-volume semiconductor manufacturing: gate-all-around transistors (RibbonFET) and backside power delivery (PowerVia).'

來源：sec.gov

The FY2025 10-K states 'Intellectual property is an essential differentiator for our business' and details 380 active U.S. utility patents, 252 active international patents, trade secrets around cell printing, and a purpose-built copy-exact Newark manufacturing facility — the moat rests on proprietary solid-oxide technology and manufacturing know-how, not network effects or locked-in customers (Item 1, Intellectual Property / Manufacturing Facilities).

來源：sec.gov

The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power."

來源：sec.gov

The FY2025 10-K still opens 'We are a global leader in the design and manufacturing of CPUs', yet concedes lost share 'in both client and data center markets' and a spend shift 'toward GPUs optimized for AI workloads' where Intel participates via 'Xeon, AI PCs, Arc GPUs and our open software stack' plus 'inference-optimized GPUs on a targeted annual cadence' — following the AI compute market rather than setting its pace.

來源：sec.gov

Scoped to fuel-cell-based onsite power for datacenters: Energy Changemakers (2026-07-04) positions Bloom as the market leader in fuel-cell deployment for AI datacenters — Brookfield framework expanded $5B→$25B, Oracle up to 2.8 GW, Equinix 100+ MW across 19 US datacenters, AEP gigawatt-scale — with FuelCell Energy the named challenger at smaller aggregate scale (~450/380/360 MW deals). In onsite power broadly (vs. turbines and engines) Bloom is one option among several (energychangemakers.com/fuel-cells-gain-ground-in-data-centers/).

來源：sec.gov

The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date."

來源：sec.gov

The FY2025 10-K states the mechanism itself: higher-priced products 'have lower margins as they are produced at external foundries rather than in our manufacturing facilities. To the extent demand shifts from our higher-margin to lower-margin products in any of our market segments, our gross margin percentage has decreased and may decrease again' — plus $878 million of 2025 inventory reserves on the early Intel 18A ramp.

來源：sec.gov

Q2 2026 release: GAAP gross margin 33.4%, up 668 bps YoY, with 34.3% non-GAAP and raised FY26 guidance of ~34% non-GAAP gross margin — margin expansion during a supply-constrained turbine market suggests real but cyclical pricing leverage; the FY2025 10-K frames the core competition as grid electricity and combustion OEMs on cost, which caps pricing through the cycle (sec.gov/Archives/edgar/data/1664703/000162828026050150/ex991_q226financialresults.htm).

來源：sec.gov

Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries."

來源：sec.gov

x86 compute incumbent and would-be US leading-edge foundry; its 18A/14A ramp is the main Western alternative to TSMC at the leading edge.

Onsite prime-power supplier to AI infrastructure: per the FY2025 10-K, AEP is procuring up to 1 GW of Bloom fuel cells for AI datacenter loads, Brookfield established a financing framework (up to $5.0B over five years at signing, per the 10-K) housed in an AI Infrastructure Fund, and SK ecoplant (a ~2.5% Class A holder) distributes and co-assembles in Korea; the Q2 2026 release adds that all major U.S. hyperscalers plus over a dozen neoclouds, AI labs, and colocation operators have approved Bloom's systems.

A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish.

• AI accelerators (Gaudi and inference-optimized GPUs) 利基市場 · 中等 來源：sec.gov
• Intel Core / Core Ultra (client PC CPUs) 領先 · 中等 來源：sec.gov
• Intel Foundry (leading-edge contract manufacturing) 利基市場 · 深 來源：sec.gov
• Intel Xeon (data center CPUs) 領先 · 中等 來源：sec.gov

• AI Datacenter Power Deployments 領先 · 中等 來源：energychangemakers.com
• Bloom Electrolyzer 未知 · 中等 來源：sec.gov
• Energy Server 領先 · 中等 來源：sec.gov

• Intismeran autogene (mRNA-4157) 未知 · 中等 來源：sec.gov
• Spikevax 前三 · 中等 來源：sec.gov
• mNEXSPIKE 前三 · 中等 來源：sec.gov
• mRESVIA 挑戰者 · 中等 來源：sec.gov
• mRNA-1010 seasonal influenza vaccine 未知 · 中等 來源：sec.gov

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →